Literature DB >> 25552651

A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.

Lu-Chen Weng1, Mary Cushman2, James S Pankow1, Saonli Basu3, Eric Boerwinkle4, Aaron R Folsom1, Weihong Tang5.   

Abstract

Reduced activated partial thromboplastin time (aPTT) is a risk marker for incident and recurrent venous thromboembolism (VTE). Genetic factors influencing aPTT are not well understood, especially in populations of non-European ancestry. The present study aimed to identify aPTT-related gene variants in both European Americans (EAs) and African Americans (AAs). We conducted a genetic association study for aPTT in 9719 EAs and 2799 AAs from the Atherosclerosis Risk in Communities (ARIC) study. Using the Candidate Gene Association Resource (CARe) consortium candidate gene array, the analyses were based on ∼50 000 SNPs in ∼2000 candidate genes. In EAs, the analyses identified a new independent association for aPTT in F5 (rs2239852, P-value = 1.9 × 10(-8)), which clusters with a coding variant rs6030 (P-value = 7.8 × 10(-7)). The remaining significant signals were located on F5, HRG, KNG1, F11, F12 and ABO and have been previously reported in EA populations. In AAs, significant signals were identified in KNG1, HRG, F12, ABO and VWF, with the leading variants in KNG1, HRG and F12 being the same as in the EAs; the significant variant in VWF (rs2229446, P-value = 1.2 × 10(-6)) was specific to the AA sample (minor allele frequency = 19% in AAs and 0.2% in EAs) and has not been previously reported. This is the first study to report aPTT-related genetic variants in AAs. Our findings in AAs demonstrate transferability of previously reported associations with KNG1, HRG and F12 in EAs. We also identified new associations at F5 in EAs and VWF in AAs that have not been previously reported for aPTT.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552651      PMCID: PMC4375421          DOI: 10.1093/hmg/ddu732

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  43 in total

1.  Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.

Authors:  G Hron; S Eichinger; A Weltermann; P Quehenberger; W M Halbmayer; P A Kyrle
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  Heritability of hemostasis phenotypes and their correlation with type 2 diabetes status in Mexican Americans.

Authors:  Diane M Warren; José Manuel Soria; Juan Carlos Souto; Anthony Comuzzie; Jordi Fontcuberta; John Blangero; Jean W MacCluer; Laura Almasy
Journal:  Hum Biol       Date:  2005-02       Impact factor: 0.553

3.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

Review 4.  How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults.

Authors:  Arif H Kamal; Ayalew Tefferi; Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2007-07       Impact factor: 7.616

5.  Activated partial thromboplastin time and risk of future venous thromboembolism.

Authors:  Neil A Zakai; Tetsuya Ohira; Richard White; Aaron R Folsom; Mary Cushman
Journal:  Am J Med       Date:  2008-03       Impact factor: 4.965

6.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

7.  von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.

Authors:  A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom
Journal:  J Thromb Haemost       Date:  2006-10-16       Impact factor: 5.824

8.  Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.

Authors:  Cristina Legnani; Silvia Mattarozzi; Michela Cini; Benilde Cosmi; Elisabetta Favaretto; Gualtiero Palareti
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

9.  Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies?

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Poli; Gian Luca Salvagno; Martina Montagnana; Gian Cesare Guidi
Journal:  Blood Coagul Fibrinolysis       Date:  2007-06       Impact factor: 1.276

10.  Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies.

Authors:  Brendan J Keating; Sam Tischfield; Sarah S Murray; Tushar Bhangale; Thomas S Price; Joseph T Glessner; Luana Galver; Jeffrey C Barrett; Struan F A Grant; Deborah N Farlow; Hareesh R Chandrupatla; Mark Hansen; Saad Ajmal; George J Papanicolaou; Yiran Guo; Mingyao Li; Stephanie Derohannessian; Paul I W de Bakker; Swneke D Bailey; Alexandre Montpetit; Andrew C Edmondson; Kent Taylor; Xiaowu Gai; Susanna S Wang; Myriam Fornage; Tamim Shaikh; Leif Groop; Michael Boehnke; Alistair S Hall; Andrew T Hattersley; Edward Frackelton; Nick Patterson; Charleston W K Chiang; Cecelia E Kim; Richard R Fabsitz; Willem Ouwehand; Alkes L Price; Patricia Munroe; Mark Caulfield; Thomas Drake; Eric Boerwinkle; David Reich; A Stephen Whitehead; Thomas P Cappola; Nilesh J Samani; A Jake Lusis; Eric Schadt; James G Wilson; Wolfgang Koenig; Mark I McCarthy; Sekar Kathiresan; Stacey B Gabriel; Hakon Hakonarson; Sonia S Anand; Muredach Reilly; James C Engert; Deborah A Nickerson; Daniel J Rader; Joel N Hirschhorn; Garret A Fitzgerald
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

View more
  2 in total

1.  Molecular basis of coronary artery dilation and aneurysms in patients with Kawasaki disease based on differential protein expression.

Authors:  Wanting Liu; Chaowu Liu; Li Zhang; Xiaofei Xie; Xiaoqiong Gu; Chuanlan Sang; Mingguo Xu; Weijun Xu; Hongling Jia
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

2.  Genetic effects of BDKRB2 and KNG1 on deep venous thrombosis after orthopedic surgery and the potential mediator.

Authors:  Qingfeng Wang; Guoping Cheng; Xiaohui Wang; Dandan Wang; Yanmei Yang; Ke Chen; Jiumin Ye; Zhong Qing
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.